Anaemia: FIND-CKD: Intravenous iron in predialysis CKD

Nature Reviews Nephrology

Volumn 10, Issue 9, 2014, Pages 488-489

  Fishbane, Steven ^a   Hazzan, Azzour D ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON; FERRIC ION; MALTOSE;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIALYSIS; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEALTH SURVEY; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFECTION; IRON DEFICIENCY; IRON THERAPY; MORTALITY; OXIDATIVE STRESS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SHORT FORM 36; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; BLOOD; FEMALE; MALE; RENAL INSUFFICIENCY, CHRONIC;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; IRON; MALE; MALTOSE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84906933619     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.139     Document Type: Short Survey

References (10)

1. Fishbane, S., Pollack, S., Feldman, H. I. & Joffe, M. M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004 Clin. J. Am. Soc. Nephrol. 4, 57-61 (2009).
2. Stancu, S. et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am. J. Kidney Dis. 55, 639-647 (2010).
3. Vadasz, D., Ries, V. & Oertel, W. H. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep Med. 11, 1214-1216 (2013).
4. Macdougall, I. C. et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol. Dial. Transplant. http://dx.doi.org/10. 1093/ndt/gfu201.
5. Pfeffer, M. A. et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
6. Singh, A. K. et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
7. Manns, B. J. & Tonelli, M. The new FDA labeling for ESA-implications for patients and providers. Clin. J. Am. Soc. Nephrol. 7, 348-353 (2012).
8. Agarwal, R., Vasavada, N., Sachs, N. G. & Chase, S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 65, 2279-2289 (2004).
9. Sengoelge, G. et al. Impairment of transendothelial leukocyte migration by iron complexes. J. Am. Soc. Nephrol. 14, 2639-2644 (2003).
10. The European Medicines agency EU clinical trials register [online] https://www.clinicaltrialsregister.eu/ctr-search/trial/2013%20002267%2025/GB (2014).